XBiotech is a biopharmaceutical company that develops therapeutic antibodies for treating inflammatory conditions, infectious diseases, and cancer.

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

COM:XBIOTECH

XBiotech

Last Close

6.49

21/11 20:47

Market Cap

190.97M

Beta: -

Volume Today

20.06K

Avg: -

locale

market

industry

website

ipo date

competitor of

Metrics